SEARCH:   Advanced

Blood, 1 April 2005, Vol. 105, No. 7, pp. 2949-2951. Prepublished online as a Blood First Edition Paper on November 30, 2004; DOI 10.1182/blood-2004-08-3231. This Article Full Text Full Text (PDF) All Versions of this Article: 2004-08-3231v1 105/7/2949    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Palladini, G. Articles by Merlini, G. Search for Related Content PubMed PubMed Citation Articles by Palladini, G. Articles by Merlini, G. Related Collections Neoplasia Free Research Articles Brief Reports Clinical Trials and Observations Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  NEOPLASIA Brief report The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL) Giovanni Palladini, Vittorio Perfetti, Stefano Perlini, Laura Obici, Francesca Lavatelli, Riccardo Caccialanza, Rosangela Invernizzi, Benedetto Comotti, and Giampaolo Merlini From the Center for Amyloidosis, Biotechnology Research Laboratories, Pavia; the Departments of Biochemistry, Internal Medicine, and Applied Health Sciences/Human Nutrition Unit, University Hospital Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)—Policlinico San Matteo and University of Pavia; and the Humanitas-Gavazzeni Clinic, Bergamo, Italy. Based on the efficacy of thalidomide in multiple myeloma and on its synergy with dexamethasone on myeloma plasma cells, we evaluated the combination of thalidomide (100 mg/d, with 100-mg increments every 2 weeks, up to 400 mg) and dexamethasone (20 mg on days 1-4) every 21 days in 31 patients with primary amyloidosis (AL) whose disease was refractory to or had relapsed after first-line therapy. Eleven (35%) patients tolerated the 400 mg/d thalidomide dose. Overall, 15 (48%) patients achieved hematologic response, with 6 (19%) complete remissions and 8 (26%) organ responses. Median time to response was 3.6 months (range, 2.5-8.0 months). Treatment-related toxicity was frequent (65%), and symptomatic bradycardia was a common (26%) adverse reaction. The combination of thalidomide and dexamethasone is rapidly effective and may represent a valuable second-line treatment for AL. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Light chains ahoy: pirating Thal/Dex for AL too Raymond L. Comenzo Blood 2005 105: 2625. [Full Text] [PDF] This article has been cited by other articles: D. E. Reece, V. Sanchorawala, U. Hegenbart, G. Merlini, G. Palladini, J.-P. Fermand, R. A. Vescio, X. Liu, Y. A. Elsayed, A. Cakana, et al. Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study Blood, August 20, 2009; 114(8): 1489 - 1497. [Abstract] [Full Text] [PDF] G. Palladini and G. Merlini Current treatment of AL amyloidosis Haematologica, August 1, 2009; 94(8): 1044 - 1048. [Full Text] [PDF] I. I. van Gameren, M. H. van Rijswijk, J. Bijzet, E. Vellenga, and B. P. Hazenberg Histological regression of amyloid in AL amyloidosis is exclusively seen after normalization of serum free light chain Haematologica, August 1, 2009; 94(8): 1094 - 1100. [Abstract] [Full Text] [PDF] S. Girnius, D. C. Seldin, M. Skinner, K. T. Finn, K. Quillen, G. Doros, and V. Sanchorawala Hepatic response after high-dose melphalan and stem cell transplantation in patients with AL amyloidosis associated liver disease Haematologica, July 1, 2009; 94(7): 1029 - 1032. [Abstract] [Full Text] [PDF] E. T.H. Yeh and C. L. Bickford Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J. Am. Coll. Cardiol., June 16, 2009; 53(24): 2231 - 2247. [Abstract] [Full Text] [PDF] G. Bollee, B. Guery, D. Joly, R. Snanoudj, B. Terrier, M. Allouache, L. Mercadal, M.-N. Peraldi, B. Viron, C. Fumeron, et al. Presentation and Outcome of Patients with Systemic Amyloidosis Undergoing Dialysis Clin. J. Am. Soc. Nephrol., March 1, 2008; 3(2): 375 - 381. [Abstract] [Full Text] [PDF] A. D. Wechalekar, H. J. Lachmann, M. Offer, P. N. Hawkins, and J. D. Gillmore Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease Haematologica, February 1, 2008; 93(2): 295 - 298. [Abstract] [Full Text] [PDF] V. Sanchorawala, M. Skinner, K. Quillen, K. T. Finn, G. Doros, and D. C. Seldin Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation Blood, November 15, 2007; 110(10): 3561 - 3563. [Abstract] [Full Text] [PDF] R. Sitia, G. Palladini, and G. Merlini Bortezomib in the treatment of AL amyloidosis: targeted therapy? Haematologica, October 1, 2007; 92(10): 1302 - 1307. [Full Text] [PDF] E. Kastritis, A. Anagnostopoulos, M. Roussou, S. Toumanidis, C. Pamboukas, M. Migkou, A. Tassidou, I. Xilouri, S. Delibasi, E. Psimenou, et al. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone Haematologica, October 1, 2007; 92(10): 1351 - 1358. [Abstract] [Full Text] [PDF] G. Palladini, P. Russo, M. Nuvolone, F. Lavatelli, V. Perfetti, L. Obici, and G. Merlini Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis Blood, July 15, 2007; 110(2): 787 - 788. [Full Text] [PDF] V. Sanchorawala, D. G. Wright, M. Rosenzweig, K. T. Finn, S. Fennessey, J. B. Zeldis, M. Skinner, and D. C. Seldin Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial Blood, January 15, 2007; 109(2): 492 - 496. [Abstract] [Full Text] [PDF] A. D. Wechalekar, H. J. B. Goodman, H. J. Lachmann, M. Offer, P. N. Hawkins, and J. D. Gillmore Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis Blood, January 15, 2007; 109(2): 457 - 464. [Abstract] [Full Text] [PDF] A. Dispenzieri, M. Q. Lacy, S. R. Zeldenrust, S. R. Hayman, S. K. Kumar, S. M. Geyer, J. A. Lust, J. B. Allred, T. E. Witzig, S. V. Rajkumar, et al. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis Blood, January 15, 2007; 109(2): 465 - 470. [Abstract] [Full Text] [PDF] L. M. Dember Amyloidosis-Associated Kidney Disease J. Am. Soc. Nephrol., December 1, 2006; 17(12): 3458 - 3471. [Abstract] [Full Text] [PDF] V. Sanchorawala Light-Chain (AL) Amyloidosis: Diagnosis and Treatment Clin. J. Am. Soc. Nephrol., November 1, 2006; 1(6): 1331 - 1341. [Abstract] [Full Text] [PDF] G. Merlini and M. J. Stone Dangerous small B-cell clones Blood, October 15, 2006; 108(8): 2520 - 2530. [Abstract] [Full Text] [PDF] H. P. Sviggum, M. D. P. Davis, S. V. Rajkumar, and A. Dispenzieri Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma. Arch Dermatol, October 1, 2006; 142(10): 1298 - 1302. [Abstract] [Full Text] [PDF] S. V. Rajkumar, A. Dispenzieri, and R. A. Kyle Monoclonal Gammopathy of Undetermined Significance, Waldenstrom Macroglobulinemia, AL Amyloidosis, and Related Plasma Cell Disorders: Diagnosis and Treatment Mayo Clin. Proc., May 1, 2006; 81(5): 693 - 703. [Abstract] [Full Text] [PDF] S. O. Schonland, H. Lokhorst, A. Buzyn, V. Leblond, U. Hegenbart, G. Bandini, A. Campbell, E. Carreras, A. Ferrant, L. Grommisch, et al. Allogeneic and syngeneic hematopoietic cell transplantation in patients with amyloid light-chain amyloidosis: a report from the European Group for Blood and Marrow Transplantation Blood, March 15, 2006; 107(6): 2578 - 2584. [Abstract] [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020